Purchase Ibrance (Palbociclib) 125 mg

1. Indications:

Palbokin (Palbociclib) 125 mg is indicated for the treatment of:

• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
• HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.

2. Pharmacology:

Palbokin (Palbociclib) 125 mg exerts its pharmacological effects by selectively inhibiting cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), proteins involved in regulating the cell cycle. By inhibiting CDK4/6, Palbokin blocks the progression of the cell cycle from the G1 phase to the S phase, leading to cell cycle arrest and inhibition of cancer cell proliferation.

3. Dosage and Administration:

The recommended dosage of Palbokin (Palbociclib) 125 mg may vary depending on the specific breast cancer subtype being treated and individual patient characteristics. Typically, the prescribed dose is 125 mg taken orally once daily for 21 consecutive days, followed by 7 days off treatment, constituting a complete cycle of 28 days. Palbociclib should be administered in combination with either an aromatase inhibitor or fulvestrant, as determined by the treating healthcare provider.

4. Interaction:

Palbokin (Palbociclib) 125 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Palbociclib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Palbociclib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Palbokin (Palbociclib) 125 mg may include:

• Neutropenia (low white blood cell count)
• Fatigue
• Nausea
• Infections
• Alopecia (hair loss)
• Diarrhea

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Palbokin (Palbociclib) 125 mg, patients should be aware of the following precautions:

• Palbociclib may cause neutropenia, which can increase the risk of infections. Patients should undergo regular monitoring of blood cell counts during treatment.
• Hepatotoxicity, including elevated liver enzymes, has been reported with Palbociclib. Liver function tests should be performed before starting treatment and periodically thereafter.
• Palbociclib may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least three weeks after the last dose.

7. Overdose Effects:

In case of overdose with Palbokin (Palbociclib) 125 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Palbociclib overdose, and patients should seek immediate medical attention if overdose is suspected.